Nobori Dual Antiplatelet Therapy as Appropriate Duration
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 3773 participants.
Also called NCT01514227
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 3,773 participants
- Sponsor
- Associations for Establishment of Evidence in Interventions
- Registry
-
NCT01514227
-
- Other papers using this trial's data
- Dual Antiplatelet Therapy for 6 Versus 18 Months After Biodegradable Polymer Drug-Eluting Stent Implantation
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Japan
- Registry status
- Completed
Technical summary
Registry record NCT01514227. Randomized; no masking; primary purpose treatment. Start 2011-12 (registry gives no type); primary completion 2016-06 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Nobori Dual Antiplatelet Therapy as Appropriate Duration
- Condition
- Coronary Artery Disease
- Intervention (Drug)
- Aspirin or thienopyridine
- Intervention (Drug)
- Aspirin and thienopyridine
- Lead sponsor
- Associations for Establishment of Evidence in Interventions
Record details
- Record id
cardio:ct-nct01514227- Content hash
1f64d5063f37398199f110449103370ef43a2f681bdead955c5650d2a88ae265